I do not think it is gutsy, I would say the science proves that our drug is completely superior. As was stated in today's video, Dr. Lalazari says the only benefit seen from Remdesivir is a slight decrease in hospitalization times, but that the side effects of Remdesivir stop quite a few patients from even participating. The disease attacks organs such as the liver and kidneys, but Remdesivir also causes toxicity in the liver and kidneys, so half of the patients can't even use this drug and would likely pass away. This to me is a no brainer. Leronlimab wins hands down.

I like your comment below, but honestly, none of their drugs have proven safe to use, so we would not even need them. I believe, if there is not a buyout, Gilead is going to be knocking on death's door. They have put so much money into other small companies, and most of them have not panned out. I.E. NASH and other HIV drugs. Once we get combination therapy, we will be taking a huge bite out of their profits, and eventually, with Mono, we will become the alpha male in this pack of wolves.

Another point, we are receiving over 1 million viles by mid-June, beginning of July period, I think we are planning something very large.

All IMO...